Cipher Reports Third Quarter Results

– Quarter Highlighted by 28% Revenue Growth, $2.3 Million in Cash Flow from Operations and Strong Advancement of Pre-Commercial Portfolio –

MISSISSAUGA, ON, Nov. 4, 2015 - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and nine months ended September 30, 2015.

"Our 28% revenue growth in Q3 2015 was driven by our recent acquisition of Innocutis and continued growth of Epuris^® & Vaniqa^® in Canada, as we continue to show strong progress in transforming Cipher from a royalty stream business into a customer-centric dermatology company with multiple high-growth opportunities," said Shawn Patrick O'Brien, President and CEO.

Tetraphase Pharmaceuticals Reports Third-Quarter 2015 Financial Results

WATERTOWN, Mass., Nov. 2, 2015 Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the quarter ended September 30, 2015.

"Despite the recent setback with the results of the IGNITE2 clinical trial in complicated urinary tract infections, we believe that we have a body of clinical and preclinical data supporting eravacycline as a potential antibiotic treatment option for patients with serious infections, particularly those caused by difficult-to-treat Gram-negative bacteria," said Guy Macdonald, Tetraphase's President and Chief Executive Officer. "We look forward to discussions with the regulatory agencies on our path forward and providing an update after we have received regulatory guidance, which we anticipate by the end of this year."

Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results

-- Total Revenues of $62.2 Million in Third Quarter -- -- EXPAREL® Net Revenues of $59.7 Million in Third Quarter -- -- Conference Call Today at 9 a.m. ET --

PARSIPPANY, N.J., Oct. 27, 2015 --  Pacira Pharmaceuticals, Inc. (PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2015.

“Third quarter EXPAREL revenues grew 19 percent over the same period last year,” said Dave Stack, chief executive officer and chairman of Pacira. “These positive results, in a quarter that is seasonally low on procedure volume, demonstrate the continued progress in addressing the marketplace challenges that have impacted this year’s sales trajectory. We remain confident in our outlook as we position ourselves for future growth on multiple fronts. We continue to make strategic appointments to key leadership roles and further the development of internal and external opportunities for EXPAREL and beyond.”

CASI Pharmaceuticals Receives EU Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma

ROCKVILLE, Md., Oct. 14, 2015 -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces that its oncology drug candidate, ENMD-2076, has received Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of hepatocellular carcinoma (HCC), including fibrolamellar carcinoma (FLC), a rare type of HCC.

The designation provides CASI with 10 years of market exclusivity in EU after ENMD-2076 receives marketing authorization there. The product was also granted Orphan Drug designation for the treatment of HCC by US Food and Drug Administration (FDA) in 2014, which provides CASI with a 7-year market exclusivity in the country after its New Drug Application approval.